Aptevo Therapeutics Inc Stock Price, News & Analysis

Aptevo (NASDAQ:APVO) presented first preclinical data for its trispecific antibody candidate APVO451 at the Society for Immunotherapy of Cancer Annual Meeting on November 8, 2025. APVO451 targets nectin-4 to localize activity, uses a CRIS-7-derived CD3 binding domain to activate T cells without observed cytokine release syndrome in related programs, and engages CD40 to restore antigen-presenting cell function.

Key preclinical findings showed tumor-localized T‑cell and APC activation, superior elimination of nectin-4+ tumor cells versus a standard CD3 engager in suppressive tumor models, and ongoing IND‑enabling preclinical studies.

Aptevo Therapeutics (Nasdaq:APVO) reported 3Q25 results and a business update on November 6, 2025. Key clinical highlights include 89% remission among evaluable frontline AML patients across two trials treated with mipletamig combinations and no cytokine release syndrome (CRS) observed in those frontline patients to date. The Company introduced two trispecific T-cell engagers, APVO451 and APVO452, expanding its CD3 portfolio to five molecules. Financially, Aptevo raised $18.7M in Q3 and $4.1M post-quarter, holding $21.1M cash at 9/30/25 (pro forma $25.2M) and stating runway into 4Q26.

Aptevo (Nasdaq:APVO) announced participation in multiple financial, industry and scientific conferences in Q4 2025 to highlight clinical and R&D progress.

Key events:

• ROTH Healthcare Opportunities – Oct 9, 2025 (NYC): panel on novel AML therapies and mipletamig trial outcomes.
• BIO-Europe – Nov 3-5, 2025 (Vienna) with digital partnering Nov 11-12.
• SITC 2025 – Nov 5-9: R&D poster on a trispecific targeting Nectin-4, CD3 and CD40.
• ASH 2025 – Dec 6-9: interim Phase 1b/2 RAINIER results for mipletamig in frontline AML.

Investor meetings available by contacting investor relations.

Aptevo Therapeutics (NASDAQ:APVO) announced breakthrough results from Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed AML patients unfit for intensive chemotherapy.

Key highlights include a 100% remission rate (CR/CRi) at the highest dose level, with 40% of patients achieving MRD-negative status. Notably, the trial reported no dose-limiting toxicities or cytokine release syndrome, demonstrating a favorable safety profile. The trial is progressing with Cohort 4 now open for enrollment, and results are expected to be presented at a major medical conference in Q4.

Aptevo Therapeutics (NASDAQ:APVO) has expanded its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumors. These therapeutics leverage the company's proprietary ADAPTIR-FLEX platform and build upon clinical validation from mipletamig, their lead CD3-directed candidate.

APVO452 targets PSMA, CD3, and CD40 for prostate cancers, while APVO451 targets Nectin-4, CD3, and CD40 for various solid tumors. Both therapeutics are designed to simultaneously engage tumor antigens, activate T cells, and modulate immunosuppressive cells in the tumor microenvironment.

This expansion brings Aptevo's pipeline to eight bispecific and trispecific candidates, including five molecules utilizing their CRIS-7-derived CD3 pathway, positioning them as a leader in next-generation T cell engagers for both hematologic and solid tumor cancers.

Aptevo Therapeutics (Nasdaq:APVO) highlighted APVO442, its preclinical CD3-engaging bispecific antibody for prostate cancer treatment. Built on the company's ADAPTIR-FLEX platform, APVO442 uses the same CRIS-7-derived anti-CD3 binding domain as mipletamig but is specifically engineered for solid tumors.

The candidate is designed to selectively activate T cells within PSMA-expressing tumor microenvironment, potentially offering improved safety and maintained anti-tumor potency. Preclinical data demonstrates effective localization to prostate tumors while potentially sparing healthy tissue.

The targeted market is significant, with prostate cancer being the second most common cancer in men, representing over 300,000 new U.S. cases annually. The global treatment market, currently at $14 billion, is projected to reach $24 billion within the next decade.

Aptevo Therapeutics (Nasdaq:APVO) reported Q2 2025 financial results and significant clinical progress. The company's lead candidate mipletamig achieved an 85% remission rate in frontline AML patients across two trials. Aptevo expanded its CD3 bispecific portfolio by introducing APVO455, a Nectin-4 x CD3 bispecific targeting multiple solid tumors.

The company raised $15.9 million in Q2 2025, extending its cash runway into late Q4 2025, with an additional $25 million equity line of credit secured. Q2 financial results showed cash position of $9.4 million and a net loss of $6.2 million ($8.40 per share), compared to a $5.9 million loss in Q2 2024.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotech company, has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules, raising $8 million in gross proceeds. The offering included 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 shares at $3.25 per share. Each common stock share comes with five Common Warrants exercisable upon stockholder approval, with a five-year expiration term. Roth Capital Partners served as the placement agent. The company plans to use the proceeds for clinical development of its product candidates, working capital, and general corporate purposes.

Aptevo Therapeutics (NASDAQ: APVO) has expanded its CD3-directed portfolio with APVO455, a new preclinical candidate targeting Nectin-4+ cancers. The company now has three CD3-engaging molecules sharing the CRIS-7 derived binding domain: mipletamig (CD123 x CD3) in Phase 1b/2 for AML with 85% remission rate, APVO442 (PSMA x CD3) for prostate cancer in preclinical development, and APVO455 (Nectin-4 x CD3) for multiple solid tumors. The CRIS-7 platform has demonstrated strong clinical validation through mipletamig's performance, where over 100 patients across three trials showed no cytokine release syndrome in initial cohorts. This expansion represents Aptevo's strategic move from hematologic to solid tumors, with a focus on developing therapeutics that combine tumor-specific immune activation with limited systemic toxicity.